Anuncio • Mar 18
Gabather AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 4.16 million. Gabather AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 4.16 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 118,857,138
Price\Range: SEK 0.035
Transaction Features: Subsequent Direct Listing New Risk • Sep 01
New major risk - Negative shareholders equity The company has negative equity. Total equity: -kr983k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.1m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-kr983k). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr8.31m market cap, or US$878.5k). Anuncio • May 26
Gabather AB (publ), Annual General Meeting, Jun 30, 2025 Gabather AB (publ), Annual General Meeting, Jun 30, 2025, at 11:00 W. Europe Standard Time. Location: in the cerebrum conference room, at forskargatan 20 g, building 212, floor 5, 151 36 sodertalje. Sweden Anuncio • Mar 20
Gabather AB (publ) has completed a Composite Units Offering. Gabather AB (publ) has completed a Composite Units Offering.
Security Name: Units
Security Type: Equity/Derivative Unit
Securities Offered: 7,081,046
Price\Range: SEK 0.9
Transaction Features: Rights Offering New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr7.5m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Negative equity (-kr2.7m). Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr12.5m market cap, or US$1.12m). New Risk • Sep 01
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr8.7m free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-kr3.6m). Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (kr16.4m market cap, or US$1.59m). New Risk • Jun 04
New major risk - Negative shareholders equity The company has negative equity. Total equity: -kr2.7m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr12m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Negative equity (-kr2.7m). Revenue is less than US$1m. Market cap is less than US$10m (kr31.0m market cap, or US$2.96m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding). Anuncio • May 31
Gabather AB (publ), Annual General Meeting, Jun 28, 2024 Gabather AB (publ), Annual General Meeting, Jun 28, 2024, at 14:00 W. Europe Standard Time. Location: in conference room cerebrum at forskargatan 20, g, bygg 212, floor 5, 151 36, sodertalje Sweden Anuncio • Mar 21
Gabather AB Files Two New Patent Applications to Secure Novel Findings on the Effects of GT-002 for the Treatment of Neuropsychiatric Disorders Gabather AB reported that two new US provisional patent applications based on novel findings from the EEG/fMRI target engagement study with GT-002, a selective positive allosteric GABAA-receptor modulator. The inventions relate to the medical use of GT-002 in psychiatric disorders. The claims based on inventions from the results from the company's EEG/fMRI target engagement study are both novel and unexpected and will strengthen Gabather’s intellectual property right (IPR) position in the field of GABAA receptor modulators, and the medical use of GT-002. The company's IPR strategy is to build layers of patents around the company's drug products, generating a strong and attractive IPR position for the products that generates an extended patent protection of the drug product. Gabather has an active portfolio of patents and patent applications covering key products and methods that create significant value to the company, giving Gabather the freedom to operate, product differentiation, as well as a strong negotiation position in potential agreement negotiations. GT-002 is a small molecule GABAA receptor Positive Allosteric Modulator (PAM) eliciting both tonic and phasic inhibitory currents. GT-002 improves learning and memory in preclinical models. It restores ketamine induced cognitive deficits in the discrimination learning task model, and inhibits the behavioural effects induced by phencyclidine in the in-vivo model of schizophrenia. GT-002 has been shown to be anxiolytic and to promote social interaction in rats. GT-002 targets a novel binding site on GABAA receptors, different from benzodiazepines (BZD), and has not shown any of the side effects known for BZD. Long-term treatment (28 days) with GT-002 has not shown any withdrawal symptoms upon cessation of treatment both in mice and dogs, indicating no drug abuse liability associated with this drug candidate. GT-002 has completed 3 phase I clinical trials in healthy volunteers. Both single ascending dose (SAD) and multiple ascending dose (MAD) studies have been completed. The results from these studies show that GT-002 is safe and well tolerated and that it has excellent pharmacokinetics, allowing for once-a-day oral dosing. An EEG/fMRI target engagement study in healthy volunteers aimed to determine the effects of GT-002 on brain activity across different brain regions and neuronal networks has recently been completed. Anuncio • Mar 07
Gabather AB (publ) Reports Initial Positive Results from the EEG/fMRI Target Engagement Study Gabather AB reported initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers. The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002. The secondary objective to demonstrate target engagement in human brain was also met. The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders. Clinically relevant effects of GT-002 were observed on modulation of EEG frequency band power with a significant increase in alpha band power, compared to Lorazepam at the 2-hour after treatment. This effect spanned various brain regions, including frontal and occipital areas. No significant effect of Lorazepam on EEG alpha band power compared to placebo was observed. The results suggest a distinct effect of GT-002 to modulate alpha band power across specific cortical regions. EEG alpha band power is recognized as a marker of cognitive activity such as attention and associated with relaxation and less anxiety, an increase in alpha band may be beneficial for a number of different neuropsychiatric conditions. Of particular clinical interest are the reports that negative symptoms in schizophrenia patients are associated with reduced EEG alpha band power. Anuncio • Dec 14
Gabather AB Approaches a Significant Milestone in the Clinical Development of GT-002 Gabather AB approaching a significant milestone in the clinical development of GT-002. The Company has completed 3 clinical trials so far, each showing that GT-002 is safe and well tolerated in man. The next step in the development of GT-002 is clinical studies in patients with diagnoses where effective treatments are lacking. Discussions with specialist doctors and researchers at the Karolinska Institutet have been initiated for the design of a study in individuals with genetic predispositions to develop FTD. Currently, there are no available specific treatments for FTD, and there is still no evidence of an effective symptomatic treatment. The goal is to create ground-breaking symptomatic treatment of FTD. The intended study is a pilot study with the aim of laying the foundation for a larger multi-centre study with GT-002. At the same time, Gabather is working towards orphan drug status "Orphan Drug Designation" (ODD) for GT-002, with a planned advisory meeting with the European Medicines Agency (EMA) during the first quarter of 2024. ODD enables a faster review and approval of the drug candidate, which also creates new opportunities for licensing deals. Anuncio • Oct 13
Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers Gabather announced the completion of the clinical phase of the EEG/fMRI target engagement study of GT-002 in healthy volunteers. All subjects have received the treatments, and the results show that GT-002 was well-tolerated with a favourable safety profile. The safety data confirms previous results from the two Phase 1 studies, the single ascending dose (SAD) study, and the multiple ascending dose (MAD) study with GT-002. The EEG/fMRI study was designed to evaluate the safety, tolerability, pharmacokinetics, target engagement and functional connectivity of brain networks of GT-002. The study included 26 healthy volunteer subjects, of which 17 subjects completed all treatments. Data analysis is currently in progress, and the final study report, including the EEG/fMRI results, will be available once 2CA-Braga has completed the comprehensive analysis of all the collected data. In parallel with the data analysis, preparations for the continued clinical development of GT-002 is ongoing. Board Change • Nov 16
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Olov Sterner is the most experienced director on the board, commencing their role in 2014. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Board Change • Apr 27
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Olov Sterner is the most experienced director on the board, commencing their role in 2014. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Board Change • Jan 21
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Olov Sterner is the most experienced director on the board, commencing their role in 2014. They were also the last independent director to join the board. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Is New 90 Day High Low • Feb 04
New 90-day high: kr6.44 The company is up 8.0% from its price of kr5.98 on 05 November 2020. The Swedish market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Is New 90 Day High Low • Dec 11
New 90-day low: kr5.48 The company is down 27% from its price of kr7.48 on 11 September 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Nov 16
New 90-day low: kr5.76 The company is down 32% from its price of kr8.48 on 18 August 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Oct 29
New 90-day low: kr5.96 The company is down 4.0% from its price of kr6.24 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. 